Travere Therapeutics, Inc.
TVTX
株式のランク
#3574
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
株価
$51.06
時価総額
$4.81B
変化（1日）
1.13%
変化（1年）
83.08%
国
US
取引 Travere Therapeutics, Inc. (TVTX)
カテゴリー
Healthcare
Travere Therapeutics, Inc.（TVTX）のP/S比率
October 2026 時点のP/S比率 TTM: 8.38
Travere Therapeutics, Inc. の最新の財務報告および株価によると、現在のP/S比率（TTM）は 8.38 です。2023 年末時点でのP/S比率は 4.60 でした。
Travere Therapeutics, Inc. の P/S 比率の履歴（2009 ～ 2026）
各年末時点のP/S比率
| 年 | P/S比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 8.38 | 42.23% |
| 2024 | 5.89 | 28.21% |
| 2023 | 4.60 | -27.31% |
| 2022 | 6.32 | -22.53% |
| 2021 | 8.16 | 24.96% |
| 2020 | 6.53 | 90.53% |
| 2019 | 3.43 | -38.43% |
| 2018 | 5.57 | 5.64% |
| 2017 | 5.27 | 0.57% |
| 2016 | 5.24 | -19.11% |
| 2015 | 6.48 | -40.37% |
| 2014 | 10.87 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
同業他社のP/S比率
| 企業 | P/S比率 | P/S比率の差 | 国 |
|---|---|---|---|
| 10.02 | 19.63% |
US
|
|
| 40.55 | 384.06% |
US
|
|
| 3.96 | -52.72% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 21.12% |
NL
|
